Cargando…
Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study
Clinical trials investigating cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) among patients with cardiovascular and renal disease rarely recruit patients with renal impairment, despite associations with increased risk for major adverse cardiovascular events (MACE). We investiga...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371013/ https://www.ncbi.nlm.nih.gov/pubmed/34404825 http://dx.doi.org/10.1038/s41598-021-95687-z |
_version_ | 1783739553850327040 |
---|---|
author | Baksh, Sheriza Wen, Jiajun Mansour, Omar Chang, Hsien-Yen McAdams-DeMarco, Mara Segal, Jodi B. Ehrhardt, Stephan Alexander, G. Caleb |
author_facet | Baksh, Sheriza Wen, Jiajun Mansour, Omar Chang, Hsien-Yen McAdams-DeMarco, Mara Segal, Jodi B. Ehrhardt, Stephan Alexander, G. Caleb |
author_sort | Baksh, Sheriza |
collection | PubMed |
description | Clinical trials investigating cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) among patients with cardiovascular and renal disease rarely recruit patients with renal impairment, despite associations with increased risk for major adverse cardiovascular events (MACE). We investigated the risk of MACE associated with the use of DPP-4i among these high-risk patients. Using a new-user, retrospective, cohort design, we analyzed 2010–2015 IBM MarketScan Commercial Claims and Encounters for patients with diabetes, comorbid with cardiovascular disease and/or renal impairment. We compared time to first MACE for DPP-4i versus sulfonylurea and versus metformin. Of 113,296 individuals, 9146 (8.07%) were new DPP-4i users, 17,481 (15.43%) were new sulfonylurea users, and 88,596 (78.20%) were new metformin users. Exposure groups were not mutually exclusive. DPP-4i was associated with lower risk for MACE than sulfonylurea (aHR 0.84; 95% CI 0.74, 0.93) and similar risk for MACE to metformin (aHR 1.07; 95% CI [1.04, 1.16]). DPP-4i use was associated with lower risk for MACE compared to sulfonylureas and similar risk for MACE compared to metformin. This association was most evident in the first year of therapy, suggesting that DPP-4i is a safer choice than sulfonylurea for diabetes treatment initiation in high-risk patients. |
format | Online Article Text |
id | pubmed-8371013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-83710132021-08-19 Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study Baksh, Sheriza Wen, Jiajun Mansour, Omar Chang, Hsien-Yen McAdams-DeMarco, Mara Segal, Jodi B. Ehrhardt, Stephan Alexander, G. Caleb Sci Rep Article Clinical trials investigating cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) among patients with cardiovascular and renal disease rarely recruit patients with renal impairment, despite associations with increased risk for major adverse cardiovascular events (MACE). We investigated the risk of MACE associated with the use of DPP-4i among these high-risk patients. Using a new-user, retrospective, cohort design, we analyzed 2010–2015 IBM MarketScan Commercial Claims and Encounters for patients with diabetes, comorbid with cardiovascular disease and/or renal impairment. We compared time to first MACE for DPP-4i versus sulfonylurea and versus metformin. Of 113,296 individuals, 9146 (8.07%) were new DPP-4i users, 17,481 (15.43%) were new sulfonylurea users, and 88,596 (78.20%) were new metformin users. Exposure groups were not mutually exclusive. DPP-4i was associated with lower risk for MACE than sulfonylurea (aHR 0.84; 95% CI 0.74, 0.93) and similar risk for MACE to metformin (aHR 1.07; 95% CI [1.04, 1.16]). DPP-4i use was associated with lower risk for MACE compared to sulfonylureas and similar risk for MACE compared to metformin. This association was most evident in the first year of therapy, suggesting that DPP-4i is a safer choice than sulfonylurea for diabetes treatment initiation in high-risk patients. Nature Publishing Group UK 2021-08-17 /pmc/articles/PMC8371013/ /pubmed/34404825 http://dx.doi.org/10.1038/s41598-021-95687-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Baksh, Sheriza Wen, Jiajun Mansour, Omar Chang, Hsien-Yen McAdams-DeMarco, Mara Segal, Jodi B. Ehrhardt, Stephan Alexander, G. Caleb Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study |
title | Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study |
title_full | Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study |
title_fullStr | Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study |
title_full_unstemmed | Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study |
title_short | Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study |
title_sort | dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371013/ https://www.ncbi.nlm.nih.gov/pubmed/34404825 http://dx.doi.org/10.1038/s41598-021-95687-z |
work_keys_str_mv | AT bakshsheriza dipeptidylpeptidase4inhibitorcardiovascularsafetyinpatientswithtype2diabeteswithcardiovascularandrenaldiseasearetrospectivecohortstudy AT wenjiajun dipeptidylpeptidase4inhibitorcardiovascularsafetyinpatientswithtype2diabeteswithcardiovascularandrenaldiseasearetrospectivecohortstudy AT mansouromar dipeptidylpeptidase4inhibitorcardiovascularsafetyinpatientswithtype2diabeteswithcardiovascularandrenaldiseasearetrospectivecohortstudy AT changhsienyen dipeptidylpeptidase4inhibitorcardiovascularsafetyinpatientswithtype2diabeteswithcardiovascularandrenaldiseasearetrospectivecohortstudy AT mcadamsdemarcomara dipeptidylpeptidase4inhibitorcardiovascularsafetyinpatientswithtype2diabeteswithcardiovascularandrenaldiseasearetrospectivecohortstudy AT segaljodib dipeptidylpeptidase4inhibitorcardiovascularsafetyinpatientswithtype2diabeteswithcardiovascularandrenaldiseasearetrospectivecohortstudy AT ehrhardtstephan dipeptidylpeptidase4inhibitorcardiovascularsafetyinpatientswithtype2diabeteswithcardiovascularandrenaldiseasearetrospectivecohortstudy AT alexandergcaleb dipeptidylpeptidase4inhibitorcardiovascularsafetyinpatientswithtype2diabeteswithcardiovascularandrenaldiseasearetrospectivecohortstudy |